Exploring real-world practices and challenges of sarcoma diagnosis in Morocco: A survey-based study among 144 pathologists
Main Article Content
Sarcoma, molecular biology, immuno-histochemistry, anatomic pathology, survey, Morocco
Background and aim: Sarcoma diagnosis is a challenge for laboratories of cytopathology and anatomic pathology. We conducted this survey-based study to better elucidate real-world practices and challenges of sarcoma diagnosis.
Methods: This was a cross-sectional study using an anonymous questionnaire. The survey was distributed among pathologists using snowball sampling. Descriptive statistics were used to report the finding of this survey.
Results: A total of 144 Moroccan pathologists were surveyed. Most respondents were from academic institutions (41.7%) and those with a specialization in sarcoma diagnosis represented 57%, through training using post-graduate fellowships followed by internships abroad and inter-university diplomas. Remarkably, 36.8% of participants reported no training on sarcoma pathology during their career. Regarding frequency of sarcoma diagnosis, 64.6% of pathologists reported having received less than one case of sarcoma per week and more than 70% did not receive sufficient information from referring clinicians. The majority of pathologists reported their nonattendance in multidisciplinary meetings. Morphology and immunohistochemistry were the most frequently used diagnostic tools, while fluorescence in situ hybridization and other molecular biology techniques were accessible for only 27% and 20.1% of pathologists, respectively. Response time during pathological diagnosis of sarcoma was 14 days according to 52.8% of surveyed participants. In addition, a second opinion was needed for 66% of pathologists.
Conclusions: Specialized training on sarcoma pathology in Morocco is lacking. A national working group on sarcoma pathology is needed to provide second opinions, and therefore, improve the management of this malignancy of poor prognosis. (www.actabiomedica.it)
2. Nakayama R, Mori T, Okita Y, Shiraishi Y, Endo M. A multidisciplinary approach to soft-tissue sarcoma of the extremities. Expert Rev Anticancer Ther. 2020;20:893-900.
3. Abdou J, Elkabous M, M'rabti H, Errihani H. Les sarcomes des tissus mous: à propos de 33 cas [Soft tissue sarcoma: a report of 33 cases]. Pan Afr Med J. 2015;22:374 [French].
4. Papillard-Maréchal S, Brisse HJ, Pannier S, et al. Masses des tissus mous d'allure tumorale de l'enfant et de l'adolescent [Pseudotumoral soft tissue masses in children and adolescents]. Arch Pediatr 2015;22:14-23 [French].
5. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009;33(9):1401-8.
6. Doyle LA, Möller E, Dal Cin P, Fletcher CD, Mertens F, Hornick JL. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am J Surg Pathol 2011;35:733-41.
7. Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 2011;50:644-53.
8. Wang L, Motoi T, Khanin R, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer 2012;51:127-39.
9. Martel M, Cheuk W, Lombardi L, Lifschitz-Mercer B, Chan JK, Rosai J. Sclerosing angiomatoid nodular transformation (SANT): report of 25 cases of a distinctive benign splenic lesion. Am J Surg Pathol 2004;28:1268-79.
10. Hornick JL, Fletcher CD. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol 2011;35:190-201.
11. Coindre JM. Biologie moléculaire des sarcomes des tissus mous [Soft tissue sarcomas: clinical application of molecular biology]. Bull Cancer 2010; 97:1337-45. [French].
12. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34.
13. Neuville A, Coindre JM. Les sarcomes, exemple d’une organisation en réseau des pathologistes [Sarcomas, example of a pathologist network organization]..Bull Cancer 2013;100:1275-81.[French].
14. Gengler C, Guillou L.Tumeurs des tissus mous: rôle du pathologiste dans l’approche diagnostique [The place of the pathologist in the management of tumors of soft tissue]. Rev Med Suisse 2007;3:1726-32. [French].
15. Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol 2021;32:1348-65.
16. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults ; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984;33:37-42.
17. Fletcher CDM, Bridge JA, Hogendoorn CW, Mertens F, World Health Organization. WHO classification of tumours of soft tissue and bone. Lyon : IARC Press, 2013.
18. Pierron G, Tirode F, Lucchesi C, et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet 2012;44:461-6.
19. Ducimetière F, Coindre JM, Gouin F. et al. L’organisation française en réseau de soins pour la prise en charge des sarcomes. Oncologie 2016;18: 247-56. [French].
20. Penel N, Coindre JM, Bonvalot S, et al. Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. Eur J Cancer 2016;58:90-6.
21. Chibon F, Lagarde P, Salas S, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010;16:781-7.